- Home
- AXSM
as 07-26-2024 4:00pm EST
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.0B | IPO Year: | 2015 |
| Target Price: | $125.33 | AVG Volume (30 days): | 672.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $55.02 - $98.40 | Next Earning Date: | 08-05-2024 |
| Revenue: | $251,023,000 | Revenue Growth: | 73.58% |
| Revenue Growth (this year): | 41.82% | Revenue Growth (next year): | 78.48% |
Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | AXSM | Chief Operating Officer | May 29 '24 | Sell | $74.31 | 7,910 | $587,813.46 | 5,783 | SEC Form 4 |
| Coleman Mark | AXSM | Director | May 28 '24 | Sell | $75.14 | 5,248 | $394,332.62 | 14,600 | SEC Form 4 |
| Coleman Mark | AXSM | Director | May 28 '24 | Sell | $75.21 | 5,249 | $394,774.67 | 19,848 | SEC Form 4 |
| Jacobson Mark L. | AXSM | Chief Operating Officer | Apr 1 '24 | Sell | $77.24 | 24,662 | $1,904,942.20 | 0 | SEC Form 4 |
| JEFFS ROGER | AXSM | Director | Mar 14 '24 | Sell | $71.61 | 2,347 | $168,062.10 | 120,756 | SEC Form 4 |
| JEFFS ROGER | AXSM | Director | Mar 14 '24 | Sell | $69.70 | 16,976 | $1,183,261.15 | 120,756 | SEC Form 4 |
| JEFFS ROGER | AXSM | Director | Mar 14 '24 | Sell | $69.70 | 13,000 | $906,126.00 | 120,756 | SEC Form 4 |
Latest Axsome Therapeutics Inc. News
AXSM Breaking Stock News: Dive into AXSM Ticker-Specific Updates for Smart Investing
Benzinga
4 days ago
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Motley Fool
12 days ago
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
GlobeNewswire
16 days ago
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
Simply Wall St.
a month ago
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week
Motley Fool
a month ago
Why Axsome Therapeutics Stock Is Sinking Today
GlobeNewswire
2 months ago
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GlobeNewswire
2 months ago
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
GlobeNewswire
2 months ago
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
Compare AXSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXSM Axsome Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.